순번 | 임상시험 제목 | 적응증 | 연구설계 | 의뢰자/실시기관 | 임상단계 | NCT No | 개시일자 |
---|---|---|---|---|---|---|---|
1 | A Research Study to Compare Somapacitan Once a Week With Norditropin® Once a Day in Children Who Need Help to Grow | SGA, Turner Syndrome, Noonan Syndrome, ISS | Drug: Somapacitan|Drug: Norditropin® | Novo Nordisk A/S | Phase 3 | NCT05330325 | 2022-08-10 |
2 | Gene Therapy With hLB-001 in Pediatric Patients With Severe Methylmalonic Acidemia | Methylmalonic Acidemia | Biological: hLB-001 | LogicBio Therapeutics, Inc. | Phase 1|Phase 2 | NCT04581785 | 2021-05-29 |
3 | A Study to Evaluate the Efficacy and Safety of Factor IX Gene Therapy With PF-06838435 in Adult Males With Moderately Severe to Severe Hemophilia B | Hemophilia B | Biological: PF-06838435/ fidanacogene elaparvovec | Pfizer | Phase 3 | NCT03861273 | 2019-07-29 |
4 | Extension Study to Evaluate the Safety and Tolerability of Tezepelumab in Adults and Adolescents With Severe, Uncontrolled Asthma | Asthma | Biological: Tezepelumab|Other: Placebo | AstraZeneca|Amgen | Phase 3 | NCT03706079 | 2019-01-07 |
5 | An Induction Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 1) | Ulcerative Colitis | Drug: Mirikizumab|Drug: Placebo | Eli Lilly and Company | Phase 3 | NCT03518086 | 2018-06-18 |
6 | Long Term Follow-up Study for Patients Enrolled on the BP-004 Clinical Study | Acute Lymphoblastic Leukemia|Leukemia, Acute Myeloid (AML), Child|Lymphoma, Non-Hodgkin|Myelodysplastic Syndromes|Primary Immunodeficiency|Anemia, Aplastic|Hemoglobinopathies|Cytopenia|Fanconi Anemia|Diamond Blackfan Anemia|Thalassemia|Anemia, Sickle Cell | Drug: Rimiducid|Biological: rivogenlecleucel | Bellicum Pharmaceuticals | Phase 1|Phase 2 | NCT03733249 | 2017-01-01 |
7 | An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Adults Who Require Regular Red Blood Cell Transfusions Due to Beta (棺) Thalassemia | Erythrocyte Transfusion|Beta-Thalassemia | Drug: Luspatercept|Other: Placebo | Celgene Corporation|Acceleron Pharma, Inc. | Phase 3 | - | 2016-05-01 |
8 | Study of Safety and Efficacy of Durvalumab in Combination With Paclitaxel in Metastatic Triple Negative Breast Cancer Patients | Breast Cancer | Drug: Paclitaxel|Drug: Durvalumab | King Faisal Specialist Hospital & Research Center|AstraZeneca | Phase 1|Phase 2 | - | 2016-01-01 |
9 | Study of 1st Line Therapy Study of MEDI4736 With Tremelimumab Versus SoC in Non Small-Cell Lung Cancer (NSCLC) (NEPTUNE). | Non Small Cell Lung Carcinoma (NSCLC) | Biological: MEDI4736+Tremelimumab|Drug: Paclitaxel + carboplatin|Drug: Gemcitabine + cisplatin|Drug: Gemcitabine + carboplatin|Drug: Pemetrexed + cisplatin|Drug: Pemetrexed + carboplatin | AstraZeneca | Phase 3 | - | 2015-11-01 |
10 | A Trial of Nivolumab, or Nivolumab Plus Ipilimumab, or Nivolumab Plus Platinum-doublet Chemotherapy, Compared to Platinum Doublet Chemotherapy in Patients With Stage IV Non-Small Cell Lung Cancer (NSCLC) | Non-Small Cell Lung Cancer | Drug: Nivolumab|Drug: Ipilimumab|Drug: Carboplatin|Drug: Cisplatin|Drug: Gemcitabine|Drug: Pemetrexed | Bristol-Myers Squibb|Ono Pharmaceutical Co. Ltd | Phase 3 | - | 2015-08-01 |